HemostOD is a pre-clinical healthcare company based in Lausanne, Switzerland that manufactures universal human blood platelets entirely ex vivo using immortalized hematopoietic stem cells and proprietary bioreactor technology. By eliminating the need for human donors, the company aims to solve chronic platelet shortages that hinder treatments ranging from cancer care to trauma response. Its platform is designed to offer safer, readily available, and scalable platelet supplies while also enabling future applications in hematology and advanced therapeutic delivery. The firm is currently transitioning from proof-of-concept research to industrialization. With the latest capital infusion, HemostOD will build a commercial-scale pilot production line and prepare for a pre-IND meeting with the U.S. FDA. These steps are intended to validate manufacturing scalability and align the product with regulatory expectations. The CHF 4.3 million seed-extension financing strengthens the company’s balance sheet as it advances toward clinical development and eventual commercialization.

Total raised

$6M

Funding rounds

2

Latest round

Seed

Latest activity

Oct 2025